Is hemolysis a novel therapeutic target in COVID-19?

Front Immunol. 2022 Aug 19:13:956671. doi: 10.3389/fimmu.2022.956671. eCollection 2022.

Authors

Daiki Ousaka¹, Masahiro Nishibori²

Affiliations

¹ Department of Pharmacology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan.
² Translational Research and Drug Development, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan.

No abstract available

Keywords: CD163; COVID-19; dexamethasone; free hemoglobin; haptoglobin; hemolysis; hemopexin; sepsis.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

COVID-19*
Haptoglobins
Hematologic Tests
Hemolysis*
Hemopexin
Humans

Substances

Haptoglobins
Hemopexin